 BOSTON, Feb. 09, 2021 GLOBE NEWSWIRE -- Galecto, Inc. NASDAQ: GLTO, a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye, the Companys Chief Executive Officer, will participate in multiple upcoming investor conferences. Dr. Schambye and Jon Freve, the Companys Chief Financial Officer, will be available for 1x1 meetings with investors at all meetings. Details are as follows: 